{"id":973224,"date":"2026-06-17T10:16:21","date_gmt":"2026-06-17T14:16:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/gral-deadline-levi-korsinsky-reminds-grail-inc-investors-of-upcoming-securities-class-action-deadline\/"},"modified":"2026-06-17T10:16:21","modified_gmt":"2026-06-17T14:16:21","slug":"gral-deadline-levi-korsinsky-reminds-grail-inc-investors-of-upcoming-securities-class-action-deadline","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gral-deadline-levi-korsinsky-reminds-grail-inc-investors-of-upcoming-securities-class-action-deadline\/","title":{"rendered":"GRAL DEADLINE: Levi & Korsinsky Reminds Grail, Inc. Investors of Upcoming Securities Class Action Deadline"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Time-Sensitive: Allegations Focus on Defendants’ Refusal to Share Detailed NHS-Galleri Data, Potentially Concealing Adverse Trendlines From Investors<\/i>\n <\/p>\n

\n NEW YORK<\/span>, June 17, 2026<\/span> \/PRNewswire\/ — Levi & Korsinsky, LLP alerts investors in Grail, Inc. (NASDAQ: GRAL) of a pending securities class action. Class Period: May 13, 2025 through February 19, 2026. Check if you can recover your investment losses<\/a>\u00a0or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com<\/a>\u00a0| (212) 363-7500.<\/p>\n

\n

\n \"Levi\n <\/p>\n<\/p><\/div>\n

GRAL shares lost $51.32 per share, plunging 50.55% in a single trading session after Grail admitted its NHS-Galleri trial failed to achieve its primary endpoint. The Court has set August 4, 2026 as the deadline to apply for lead plaintiff appointment.<\/p>\n

\n The Alleged<\/span> Data Withholding Strategy<\/b>\n <\/p>\n

The lawsuit asserts that throughout the Class Period, Grail’s leadership deliberately withheld detailed results from the NHS-Galleri trial’s prevalent screening round, citing the need to protect “the integrity of the trial as a whole.” The action claims this justification masked a more troubling reality: the concealed data allegedly<\/span> contained trendlines suggesting the trial’s three-year screening duration was insufficient to demonstrate the primary endpoint of a statistically significant reduction in Stage III and IV cancers.<\/p>\n

When analysts pressed for specifics, management repeatedly deflected. On the Q1 2025 earnings call, executives confirmed the positive predictive value was “substantially higher” than 43% but stated: “We’re not sharing what that number is.” As alleged<\/span>, this selective disclosure pattern allowed the Company to promote favorable metrics while burying unfavorable signals about clinical utility.<\/p>\n

\n Selective Transparency in Multi-Cancer Early Detection<\/b>\n <\/p>\n

The securities action highlights a pattern common in diagnostic companies: sharing favorable test performance metrics while withholding clinical outcome data that would temper investor enthusiasm.<\/p>\n